DK1227095T3 - En fremgangsmåde til oprensningen af (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-2-oxazolidinon - Google Patents

En fremgangsmåde til oprensningen af (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-2-oxazolidinon

Info

Publication number
DK1227095T3
DK1227095T3 DK02008427T DK02008427T DK1227095T3 DK 1227095 T3 DK1227095 T3 DK 1227095T3 DK 02008427 T DK02008427 T DK 02008427T DK 02008427 T DK02008427 T DK 02008427T DK 1227095 T3 DK1227095 T3 DK 1227095T3
Authority
DK
Denmark
Prior art keywords
oxazolidinone
indol
dimethylamino
purification
ethyl
Prior art date
Application number
DK02008427T
Other languages
Danish (da)
English (en)
Inventor
Rajnikant Patel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1227095T3 publication Critical patent/DK1227095T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
DK02008427T 1995-08-07 1996-08-02 En fremgangsmåde til oprensningen af (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-2-oxazolidinon DK1227095T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9516145.1A GB9516145D0 (en) 1995-08-07 1995-08-07 Improved chemical synthesis
PCT/GB1996/001885 WO1997006162A1 (en) 1995-08-07 1996-08-02 One pot synthesis of 2-oxazolidinone derivatives

Publications (1)

Publication Number Publication Date
DK1227095T3 true DK1227095T3 (da) 2006-07-31

Family

ID=10778867

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02008427T DK1227095T3 (da) 1995-08-07 1996-08-02 En fremgangsmåde til oprensningen af (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-2-oxazolidinon
DK96926465T DK0843672T3 (da) 1995-08-07 1996-08-02 Enkeltreaktorsyntese af 2-oxazolidinonderivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96926465T DK0843672T3 (da) 1995-08-07 1996-08-02 Enkeltreaktorsyntese af 2-oxazolidinonderivater

Country Status (34)

Country Link
US (2) US6084103A (de)
EP (2) EP1227095B1 (de)
JP (6) JP3729503B2 (de)
KR (1) KR100670704B1 (de)
CN (3) CN1244579C (de)
AR (2) AR006515A1 (de)
AT (2) ATE227723T1 (de)
AU (1) AU718413B2 (de)
BR (1) BR9609830A (de)
CA (2) CA2227039C (de)
CZ (2) CZ301603B6 (de)
DE (2) DE69624825T2 (de)
DK (2) DK1227095T3 (de)
ES (2) ES2185790T3 (de)
GB (1) GB9516145D0 (de)
HK (2) HK1047094B (de)
HU (1) HU229966B1 (de)
IL (4) IL156733A (de)
IN (2) IN185148B (de)
MX (1) MX9801044A (de)
MY (1) MY117571A (de)
NO (2) NO311690B1 (de)
NZ (1) NZ315040A (de)
PL (1) PL188805B1 (de)
PT (2) PT843672E (de)
RO (2) RO121816B1 (de)
RU (1) RU2167875C2 (de)
SI (2) SI0843672T1 (de)
SK (1) SK285052B6 (de)
TR (1) TR199800182T1 (de)
TW (1) TW358811B (de)
UA (1) UA53625C2 (de)
WO (1) WO1997006162A1 (de)
ZA (1) ZA966711B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004088A1 (fr) * 1999-07-09 2001-01-18 Chugai Seiyaku Kabushiki Kaisha Procede de preparation de derives d'amiline
ES2204302B2 (es) 2002-08-07 2005-03-01 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
EP1812428A2 (de) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan-kristallformen
CN101248184B (zh) 2005-08-25 2013-01-16 宇部兴产株式会社 光学活性（S或R）-α-氨基酸及光学活性（S或R）-α-氨基酸酯的制造方法
EP1981860B1 (de) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Umwandlung eines aromatischen diazoniumsalzes in ein arylhydrazin
WO2008007390A2 (en) * 2006-07-10 2008-01-17 Natco Pharma Limited An improved process for purification of zolmitriptan
WO2008018090A2 (en) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd An improved process for the preparation of zolmitriptan
CZ2007158A3 (cs) * 2007-02-26 2008-10-22 Zentiva, A. S. Zpusob prípravy zolmitriptanu
CZ301538B6 (cs) * 2007-02-26 2010-04-07 Zentiva, A. S. Zpusob prípravy zolmitriptanu
CN101883766A (zh) * 2007-10-03 2010-11-10 基因里克斯(英国)有限公司 制备佐米曲普坦、其盐和溶剂化物的方法
CN101230047B (zh) * 2008-02-04 2010-08-04 江苏中威药业有限公司 一种4-取代手性噁唑烷酮类化合物的制备方法
US8906949B2 (en) 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
CN101948443B (zh) * 2010-08-17 2012-08-22 河南师范大学 一种简单、高效合成4-取代噁唑烷酮衍生物的方法
EP2691396B1 (de) 2011-03-30 2016-08-10 Brown University Enopeptine, verwendungen davon und syntheseverfahren dafür
US9006453B2 (en) 2011-09-02 2015-04-14 Emcure Pharmaceuticals Limited Process for preparation of zolmitriptan
CN102964270B (zh) * 2012-11-21 2015-01-07 合肥星宇化学有限责任公司 一种亚硫酸钠还原重氮盐合成肼的方法
CN103275075B (zh) * 2013-06-24 2015-01-07 成都天台山制药有限公司 佐米曲普坦及其制备方法
WO2016037072A2 (en) * 2014-09-04 2016-03-10 Brown University Enopeptin analogas and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
YU48855B (sh) * 1990-06-07 2002-06-19 The Wellcome Foundation Limited Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists

Also Published As

Publication number Publication date
PL188805B1 (pl) 2005-04-29
PT1227095E (pt) 2006-08-31
EP0843672A1 (de) 1998-05-27
IN189756B (de) 2003-04-19
IN185148B (de) 2000-11-25
HU229966B1 (hu) 2015-03-30
ATE227723T1 (de) 2002-11-15
CN1201460A (zh) 1998-12-09
AU718413B2 (en) 2000-04-13
SK285052B6 (sk) 2006-05-04
ES2185790T3 (es) 2003-05-01
BR9609830A (pt) 1999-03-09
AR046236A2 (es) 2005-11-30
ZA966711B (en) 1997-02-18
CN1317480A (zh) 2001-10-17
IL123171A (en) 2003-10-31
ATE325121T1 (de) 2006-06-15
AR006515A1 (es) 1999-09-08
HK1047094B (zh) 2006-10-13
TW358811B (en) 1999-05-21
TR199800182T1 (xx) 1998-05-21
ES2261545T3 (es) 2006-11-16
JP3739678B2 (ja) 2006-01-25
JP3729503B2 (ja) 2005-12-21
US6084103A (en) 2000-07-04
IL123171A0 (en) 1998-09-24
CZ301603B6 (cs) 2010-04-28
EP1227095A2 (de) 2002-07-31
RO121816B1 (ro) 2008-05-30
AU6663496A (en) 1997-03-05
HUP9900188A2 (hu) 1999-05-28
CN1244579C (zh) 2006-03-08
WO1997006162A1 (en) 1997-02-20
DE69636107T2 (de) 2007-05-03
CN1142904C (zh) 2004-03-24
NO20005187D0 (no) 2000-10-16
CA2572508C (en) 2010-03-30
MX9801044A (es) 1998-05-31
NO980522D0 (no) 1998-02-06
DE69636107D1 (de) 2006-06-08
CZ293050B6 (cs) 2004-01-14
RU2167875C2 (ru) 2001-05-27
RO119618B1 (ro) 2005-01-28
CA2227039C (en) 2007-12-04
JP2002097178A (ja) 2002-04-02
CA2227039A1 (en) 1997-02-20
NZ315040A (en) 2000-01-28
KR19990036165A (ko) 1999-05-25
HK1047094A1 (en) 2003-02-07
DE69624825T2 (de) 2003-09-04
SI0843672T1 (en) 2003-04-30
SK15498A3 (en) 1998-06-03
IL156733A0 (en) 2004-02-08
US6160123A (en) 2000-12-12
MY117571A (en) 2004-07-31
UA53625C2 (uk) 2003-02-17
EP1227095B1 (de) 2006-05-03
JP2006077025A (ja) 2006-03-23
EP1227095A3 (de) 2003-11-19
PL324881A1 (en) 1998-06-22
CN1403455A (zh) 2003-03-19
JP2002308858A (ja) 2002-10-23
JPH11513023A (ja) 1999-11-09
JP4634286B2 (ja) 2011-02-16
HK1009129A1 (en) 1999-05-28
IL148030A0 (en) 2002-09-12
CZ35298A3 (cs) 1998-06-17
CN1092657C (zh) 2002-10-16
CA2572508A1 (en) 1997-02-20
KR100670704B1 (ko) 2007-07-11
IL148030A (en) 2010-05-17
DK0843672T3 (da) 2003-02-17
HUP9900188A3 (en) 1999-11-29
GB9516145D0 (en) 1995-10-04
NO20005187L (no) 1998-02-06
JP2002037786A (ja) 2002-02-06
DE69624825D1 (de) 2002-12-19
NO311691B1 (no) 2002-01-07
NO980522L (no) 1998-02-06
SI1227095T1 (sl) 2006-08-31
JP2006225406A (ja) 2006-08-31
EP0843672B1 (de) 2002-11-13
IL156733A (en) 2007-07-04
NO311690B1 (no) 2002-01-07
PT843672E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
DK1227095T3 (da) En fremgangsmåde til oprensningen af (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-2-oxazolidinon
DK0770615T3 (da) Fremgangsmåde til fremstilling af dihalogenazolopyrimidiner
DK0845956T4 (da) Fremgangsmåde til fremstilling af en tandbörste
DK0778068T3 (da) Fremgangsmåde til afvanding af en gas
DK0754756T3 (da) Fremgangsmåde til fremstilling af L-lysin
DK1445259T3 (da) Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
DE69635853D1 (de) Gerät zur akustischen Korrektur
DE69620107T2 (de) Kristallisationsverfahren
DK0747119T3 (da) Fremgangsmåde til fremstilling af sorberingsmidler
DK0937068T3 (da) Fremgangsmåde til krystallisation af losartan
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
DK0824517T3 (da) Fremgangsmåde til fremstilling af lercanidipinhydrochlorid
DK0839138T3 (da) Fremgangsmåde til fremstilling af N-substituerede 3-hydroxypyrazoler
DK0768310T3 (da) Fremgangsmåde til fremstilling af imidazo-benzodiazepin-derivater
DK0830337T3 (da) Fremgangsmåde til hydrogenering af iminer
DK0877738T3 (da) Fremgangsmåde til fremstilling af phenylimidazolidinderivater
DK0780446T3 (da) Fremgangsmåde til fremstilling af pigmenter
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK0888168T3 (da) Fremgangsmåde til rensning af procesgasser
DK0805806T3 (da) Fremgangsmåde til fremstilling af 4,10-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxotax-11-en-13alpha-
DK0842930T3 (da) Fremgangsmåde til syntese af benzothiophener
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
DK1023292T3 (da) Fremgangsmåde til syntese af chlorpurinintermediater
DK0721929T3 (da) Fremgangsmåde til fremstilling af hydroxyalkoxybenzophenoner
DK0863874T3 (da) Fremgangsmåde til fremstilling af dioxoazabicyclohexaner